- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Drugs for Non-Small Cell Lung Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Drugs for Non-Small Cell Lung Cancer market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Drugs for Non-Small Cell Lung Cancer global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Radiofrequency Ablation (RFA) segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Drugs for Non-Small Cell Lung Cancer include Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi, and Ziopharm Oncology, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Drugs for Non-Small Cell Lung Cancer market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Market segment by Application, can be divided into
Hospitals
Clinics
Other
Market segment by players, this report covers
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Drugs for Non-Small Cell Lung Cancer product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Drugs for Non-Small Cell Lung Cancer, with revenue, gross margin and global market share of Drugs for Non-Small Cell Lung Cancer from 2019 to 2022.
Chapter 3, the Drugs for Non-Small Cell Lung Cancer competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Drugs for Non-Small Cell Lung Cancer market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Drugs for Non-Small Cell Lung Cancer research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Drugs for Non-Small Cell Lung Cancer
1.2 Classification of Drugs for Non-Small Cell Lung Cancer by Type
1.2.1 Overview: Global Drugs for Non-Small Cell Lung Cancer Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Type in 2021
1.2.3 Radiofrequency Ablation (RFA)
1.2.4 Radiation Therapy
1.2.5 Chemotherapy
1.2.6 Targeted Therapies
1.2.7 Immunotherapy
1.3 Global Drugs for Non-Small Cell Lung Cancer Market by Application
1.3.1 Overview: Global Drugs for Non-Small Cell Lung Cancer Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Drugs for Non-Small Cell Lung Cancer Market Size & Forecast
1.5 Global Drugs for Non-Small Cell Lung Cancer Market Size and Forecast by Region
1.5.1 Global Drugs for Non-Small Cell Lung Cancer Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Drugs for Non-Small Cell Lung Cancer Market Size by Region, (2017-2022)
1.5.3 North America Drugs for Non-Small Cell Lung Cancer Market Size and Prospect (2017-2028)
1.5.4 Europe Drugs for Non-Small Cell Lung Cancer Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size and Prospect (2017-2028)
1.5.6 South America Drugs for Non-Small Cell Lung Cancer Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Drugs for Non-Small Cell Lung Cancer Market Drivers
1.6.2 Drugs for Non-Small Cell Lung Cancer Market Restraints
1.6.3 Drugs for Non-Small Cell Lung Cancer Trends Analysis
2 Company Profiles
2.1 Bristol-Myers Squibb
2.1.1 Bristol-Myers Squibb Details
2.1.2 Bristol-Myers Squibb Major Business
2.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.1.4 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.2.4 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 GlaxoSmithKline Recent Developments and Future Plans
2.3 Menarini
2.3.1 Menarini Details
2.3.2 Menarini Major Business
2.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.3.4 Menarini Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Menarini Recent Developments and Future Plans
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business
2.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.4.4 Sanofi Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Sanofi Recent Developments and Future Plans
2.5 Ziopharm Oncology
2.5.1 Ziopharm Oncology Details
2.5.2 Ziopharm Oncology Major Business
2.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.5.4 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Ziopharm Oncology Recent Developments and Future Plans
2.6 Alchemia
2.6.1 Alchemia Details
2.6.2 Alchemia Major Business
2.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.6.4 Alchemia Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Alchemia Recent Developments and Future Plans
2.7 Amgen
2.7.1 Amgen Details
2.7.2 Amgen Major Business
2.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.7.4 Amgen Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Amgen Recent Developments and Future Plans
2.8 Apotex
2.8.1 Apotex Details
2.8.2 Apotex Major Business
2.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.8.4 Apotex Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Apotex Recent Developments and Future Plans
2.9 BioMarin Pharmaceutical
2.9.1 BioMarin Pharmaceutical Details
2.9.2 BioMarin Pharmaceutical Major Business
2.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.9.4 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 BioMarin Pharmaceutical Recent Developments and Future Plans
2.10 CellAct Pharma
2.10.1 CellAct Pharma Details
2.10.2 CellAct Pharma Major Business
2.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.10.4 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 CellAct Pharma Recent Developments and Future Plans
2.11 Cerulean Pharma
2.11.1 Cerulean Pharma Details
2.11.2 Cerulean Pharma Major Business
2.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.11.4 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Cerulean Pharma Recent Developments and Future Plans
2.12 Cipla
2.12.1 Cipla Details
2.12.2 Cipla Major Business
2.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.12.4 Cipla Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Cipla Recent Developments and Future Plans
2.13 Cornerstone Pharmaceuticals
2.13.1 Cornerstone Pharmaceuticals Details
2.13.2 Cornerstone Pharmaceuticals Major Business
2.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.13.4 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Cornerstone Pharmaceuticals Recent Developments and Future Plans
2.14 Curis
2.14.1 Curis Details
2.14.2 Curis Major Business
2.14.3 Curis Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.14.4 Curis Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Curis Recent Developments and Future Plans
2.15 CytRx
2.15.1 CytRx Details
2.15.2 CytRx Major Business
2.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.15.4 CytRx Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 CytRx Recent Developments and Future Plans
2.16 Eli Lilly
2.16.1 Eli Lilly Details
2.16.2 Eli Lilly Major Business
2.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.16.4 Eli Lilly Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 Eli Lilly Recent Developments and Future Plans
2.17 Exelixis
2.17.1 Exelixis Details
2.17.2 Exelixis Major Business
2.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.17.4 Exelixis Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Exelixis Recent Developments and Future Plans
2.18 Fresenius Kabi
2.18.1 Fresenius Kabi Details
2.18.2 Fresenius Kabi Major Business
2.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.18.4 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 Fresenius Kabi Recent Developments and Future Plans
2.19 Genentech
2.19.1 Genentech Details
2.19.2 Genentech Major Business
2.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.19.4 Genentech Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 Genentech Recent Developments and Future Plans
2.20 Hikma Pharmaceuticals
2.20.1 Hikma Pharmaceuticals Details
2.20.2 Hikma Pharmaceuticals Major Business
2.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.20.4 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20.5 Hikma Pharmaceuticals Recent Developments and Future Plans
2.21 Hospira
2.21.1 Hospira Details
2.21.2 Hospira Major Business
2.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.21.4 Hospira Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21.5 Hospira Recent Developments and Future Plans
2.22 Intas Pharmaceuticals
2.22.1 Intas Pharmaceuticals Details
2.22.2 Intas Pharmaceuticals Major Business
2.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.22.4 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.22.5 Intas Pharmaceuticals Recent Developments and Future Plans
2.23 Karyopharm Therapeutics
2.23.1 Karyopharm Therapeutics Details
2.23.2 Karyopharm Therapeutics Major Business
2.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.23.4 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.23.5 Karyopharm Therapeutics Recent Developments and Future Plans
2.24 Kyowa Hakko Kirin
2.24.1 Kyowa Hakko Kirin Details
2.24.2 Kyowa Hakko Kirin Major Business
2.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.24.4 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.24.5 Kyowa Hakko Kirin Recent Developments and Future Plans
2.25 Ligand Pharmaceuticals
2.25.1 Ligand Pharmaceuticals Details
2.25.2 Ligand Pharmaceuticals Major Business
2.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product and Solutions
2.25.4 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.25.5 Ligand Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Drugs for Non-Small Cell Lung Cancer Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Drugs for Non-Small Cell Lung Cancer Players Market Share in 2021
3.2.2 Top 10 Drugs for Non-Small Cell Lung Cancer Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Drugs for Non-Small Cell Lung Cancer Players Head Office, Products and Services Provided
3.4 Drugs for Non-Small Cell Lung Cancer Mergers & Acquisitions
3.5 Drugs for Non-Small Cell Lung Cancer New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Drugs for Non-Small Cell Lung Cancer Revenue and Market Share by Type (2017-2022)
4.2 Global Drugs for Non-Small Cell Lung Cancer Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Application (2017-2022)
5.2 Global Drugs for Non-Small Cell Lung Cancer Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Drugs for Non-Small Cell Lung Cancer Revenue by Type (2017-2028)
6.2 North America Drugs for Non-Small Cell Lung Cancer Revenue by Application (2017-2028)
6.3 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country
6.3.1 North America Drugs for Non-Small Cell Lung Cancer Revenue by Country (2017-2028)
6.3.2 United States Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
6.3.3 Canada Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
6.3.4 Mexico Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Drugs for Non-Small Cell Lung Cancer Revenue by Type (2017-2028)
7.2 Europe Drugs for Non-Small Cell Lung Cancer Revenue by Application (2017-2028)
7.3 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country
7.3.1 Europe Drugs for Non-Small Cell Lung Cancer Revenue by Country (2017-2028)
7.3.2 Germany Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
7.3.3 France Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
7.3.5 Russia Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
7.3.6 Italy Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Revenue by Type (2017-2028)
8.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Revenue by Application (2017-2028)
8.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region
8.3.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Revenue by Region (2017-2028)
8.3.2 China Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
8.3.3 Japan Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
8.3.4 South Korea Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
8.3.5 India Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
8.3.7 Australia Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Drugs for Non-Small Cell Lung Cancer Revenue by Type (2017-2028)
9.2 South America Drugs for Non-Small Cell Lung Cancer Revenue by Application (2017-2028)
9.3 South America Drugs for Non-Small Cell Lung Cancer Market Size by Country
9.3.1 South America Drugs for Non-Small Cell Lung Cancer Revenue by Country (2017-2028)
9.3.2 Brazil Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
9.3.3 Argentina Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue by Type (2017-2028)
10.2 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue by Application (2017-2028)
10.3 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country
10.3.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue by Country (2017-2028)
10.3.2 Turkey Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
10.3.4 UAE Drugs for Non-Small Cell Lung Cancer Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Drugs for Non-Small Cell Lung Cancer Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Drugs for Non-Small Cell Lung Cancer Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Drugs for Non-Small Cell Lung Cancer Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Drugs for Non-Small Cell Lung Cancer Revenue (USD Million) by Region (2017-2022)
Table 5. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Region (2023-2028)
Table 6. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 7. Bristol-Myers Squibb Major Business
Table 8. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 9. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 11. GlaxoSmithKline Major Business
Table 12. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 13. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Menarini Corporate Information, Head Office, and Major Competitors
Table 15. Menarini Major Business
Table 16. Menarini Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 17. Menarini Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Sanofi Corporate Information, Head Office, and Major Competitors
Table 19. Sanofi Major Business
Table 20. Sanofi Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 21. Sanofi Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Ziopharm Oncology Corporate Information, Head Office, and Major Competitors
Table 23. Ziopharm Oncology Major Business
Table 24. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 25. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Alchemia Corporate Information, Head Office, and Major Competitors
Table 27. Alchemia Major Business
Table 28. Alchemia Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 29. Alchemia Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Amgen Corporate Information, Head Office, and Major Competitors
Table 31. Amgen Major Business
Table 32. Amgen Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 33. Amgen Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Apotex Corporate Information, Head Office, and Major Competitors
Table 35. Apotex Major Business
Table 36. Apotex Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 37. Apotex Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. BioMarin Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 39. BioMarin Pharmaceutical Major Business
Table 40. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 41. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. CellAct Pharma Corporate Information, Head Office, and Major Competitors
Table 43. CellAct Pharma Major Business
Table 44. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 45. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Cerulean Pharma Corporate Information, Head Office, and Major Competitors
Table 47. Cerulean Pharma Major Business
Table 48. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 49. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Cipla Corporate Information, Head Office, and Major Competitors
Table 51. Cipla Major Business
Table 52. Cipla Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 53. Cipla Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Cornerstone Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 55. Cornerstone Pharmaceuticals Major Business
Table 56. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 57. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Curis Corporate Information, Head Office, and Major Competitors
Table 59. Curis Major Business
Table 60. Curis Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 61. Curis Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. CytRx Corporate Information, Head Office, and Major Competitors
Table 63. CytRx Major Business
Table 64. CytRx Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 65. CytRx Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 67. Eli Lilly Major Business
Table 68. Eli Lilly Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 69. Eli Lilly Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Exelixis Corporate Information, Head Office, and Major Competitors
Table 71. Exelixis Major Business
Table 72. Exelixis Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 73. Exelixis Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. Fresenius Kabi Corporate Information, Head Office, and Major Competitors
Table 75. Fresenius Kabi Major Business
Table 76. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 77. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. Genentech Corporate Information, Head Office, and Major Competitors
Table 79. Genentech Major Business
Table 80. Genentech Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 81. Genentech Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Hikma Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 83. Hikma Pharmaceuticals Major Business
Table 84. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 85. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 86. Hospira Corporate Information, Head Office, and Major Competitors
Table 87. Hospira Major Business
Table 88. Hospira Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 89. Hospira Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 90. Intas Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 91. Intas Pharmaceuticals Major Business
Table 92. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 93. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 94. Karyopharm Therapeutics Corporate Information, Head Office, and Major Competitors
Table 95. Karyopharm Therapeutics Major Business
Table 96. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 97. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 98. Kyowa Hakko Kirin Corporate Information, Head Office, and Major Competitors
Table 99. Kyowa Hakko Kirin Major Business
Table 100. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 101. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 102. Ligand Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 103. Ligand Pharmaceuticals Major Business
Table 104. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product and Solutions
Table 105. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 106. Global Drugs for Non-Small Cell Lung Cancer Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 107. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 108. Breakdown of Drugs for Non-Small Cell Lung Cancer by Company Type (Tier 1, Tier 2 and Tier 3)
Table 109. Drugs for Non-Small Cell Lung Cancer Players Head Office, Products and Services Provided
Table 110. Drugs for Non-Small Cell Lung Cancer Mergers & Acquisitions in the Past Five Years
Table 111. Drugs for Non-Small Cell Lung Cancer New Entrants and Expansion Plans
Table 112. Global Drugs for Non-Small Cell Lung Cancer Revenue (USD Million) by Type (2017-2022)
Table 113. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Type (2017-2022)
Table 114. Global Drugs for Non-Small Cell Lung Cancer Revenue Forecast by Type (2023-2028)
Table 115. Global Drugs for Non-Small Cell Lung Cancer Revenue by Application (2017-2022)
Table 116. Global Drugs for Non-Small Cell Lung Cancer Revenue Forecast by Application (2023-2028)
Table 117. North America Drugs for Non-Small Cell Lung Cancer Revenue by Type (2017-2022) & (USD Million)
Table 118. North America Drugs for Non-Small Cell Lung Cancer Revenue by Type (2023-2028) & (USD Million)
Table 119. North America Drugs for Non-Small Cell Lung Cancer Revenue by Application (2017-2022) & (USD Million)
Table 120. North America Drugs for Non-Small Cell Lung Cancer Revenue by Application (2023-2028) & (USD Million)
Table 121. North America Drugs for Non-Small Cell Lung Cancer Revenue by Country (2017-2022) & (USD Million)
Table 122. North America Drugs for Non-Small Cell Lung Cancer Revenue by Country (2023-2028) & (USD Million)
Table 123. Europe Drugs for Non-Small Cell Lung Cancer Revenue by Type (2017-2022) & (USD Million)
Table 124. Europe Drugs for Non-Small Cell Lung Cancer Revenue by Type (2023-2028) & (USD Million)
Table 125. Europe Drugs for Non-Small Cell Lung Cancer Revenue by Application (2017-2022) & (USD Million)
Table 126. Europe Drugs for Non-Small Cell Lung Cancer Revenue by Application (2023-2028) & (USD Million)
Table 127. Europe Drugs for Non-Small Cell Lung Cancer Revenue by Country (2017-2022) & (USD Million)
Table 128. Europe Drugs for Non-Small Cell Lung Cancer Revenue by Country (2023-2028) & (USD Million)
Table 129. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Revenue by Type (2017-2022) & (USD Million)
Table 130. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Revenue by Type (2023-2028) & (USD Million)
Table 131. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Revenue by Application (2017-2022) & (USD Million)
Table 132. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Revenue by Application (2023-2028) & (USD Million)
Table 133. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Revenue by Region (2017-2022) & (USD Million)
Table 134. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Revenue by Region (2023-2028) & (USD Million)
Table 135. South America Drugs for Non-Small Cell Lung Cancer Revenue by Type (2017-2022) & (USD Million)
Table 136. South America Drugs for Non-Small Cell Lung Cancer Revenue by Type (2023-2028) & (USD Million)
Table 137. South America Drugs for Non-Small Cell Lung Cancer Revenue by Application (2017-2022) & (USD Million)
Table 138. South America Drugs for Non-Small Cell Lung Cancer Revenue by Application (2023-2028) & (USD Million)
Table 139. South America Drugs for Non-Small Cell Lung Cancer Revenue by Country (2017-2022) & (USD Million)
Table 140. South America Drugs for Non-Small Cell Lung Cancer Revenue by Country (2023-2028) & (USD Million)
Table 141. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue by Type (2017-2022) & (USD Million)
Table 142. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue by Type (2023-2028) & (USD Million)
Table 143. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue by Application (2017-2022) & (USD Million)
Table 144. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue by Application (2023-2028) & (USD Million)
Table 145. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue by Country (2017-2022) & (USD Million)
Table 146. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Drugs for Non-Small Cell Lung Cancer Picture
Figure 2. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Type in 2021
Figure 3. Radiofrequency Ablation (RFA)
Figure 4. Radiation Therapy
Figure 5. Chemotherapy
Figure 6. Targeted Therapies
Figure 7. Immunotherapy
Figure 8. Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Application in 2021
Figure 9. Hospitals Picture
Figure 10. Clinics Picture
Figure 11. Other Picture
Figure 12. Global Drugs for Non-Small Cell Lung Cancer Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global Drugs for Non-Small Cell Lung Cancer Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Region (2017-2028)
Figure 15. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Region in 2021
Figure 16. North America Drugs for Non-Small Cell Lung Cancer Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe Drugs for Non-Small Cell Lung Cancer Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America Drugs for Non-Small Cell Lung Cancer Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Drugs for Non-Small Cell Lung Cancer Market Drivers
Figure 22. Drugs for Non-Small Cell Lung Cancer Market Restraints
Figure 23. Drugs for Non-Small Cell Lung Cancer Market Trends
Figure 24. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 25. GlaxoSmithKline Recent Developments and Future Plans
Figure 26. Menarini Recent Developments and Future Plans
Figure 27. Sanofi Recent Developments and Future Plans
Figure 28. Ziopharm Oncology Recent Developments and Future Plans
Figure 29. Alchemia Recent Developments and Future Plans
Figure 30. Amgen Recent Developments and Future Plans
Figure 31. Apotex Recent Developments and Future Plans
Figure 32. BioMarin Pharmaceutical Recent Developments and Future Plans
Figure 33. CellAct Pharma Recent Developments and Future Plans
Figure 34. Cerulean Pharma Recent Developments and Future Plans
Figure 35. Cipla Recent Developments and Future Plans
Figure 36. Cornerstone Pharmaceuticals Recent Developments and Future Plans
Figure 37. Curis Recent Developments and Future Plans
Figure 38. CytRx Recent Developments and Future Plans
Figure 39. Eli Lilly Recent Developments and Future Plans
Figure 40. Exelixis Recent Developments and Future Plans
Figure 41. Fresenius Kabi Recent Developments and Future Plans
Figure 42. Genentech Recent Developments and Future Plans
Figure 43. Hikma Pharmaceuticals Recent Developments and Future Plans
Figure 44. Hospira Recent Developments and Future Plans
Figure 45. Intas Pharmaceuticals Recent Developments and Future Plans
Figure 46. Karyopharm Therapeutics Recent Developments and Future Plans
Figure 47. Kyowa Hakko Kirin Recent Developments and Future Plans
Figure 48. Ligand Pharmaceuticals Recent Developments and Future Plans
Figure 49. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Players in 2021
Figure 50. Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 51. Global Top 3 Players Drugs for Non-Small Cell Lung Cancer Revenue Market Share in 2021
Figure 52. Global Top 10 Players Drugs for Non-Small Cell Lung Cancer Revenue Market Share in 2021
Figure 53. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 54. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Type in 2021
Figure 55. Global Drugs for Non-Small Cell Lung Cancer Market Share Forecast by Type (2023-2028)
Figure 56. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Application in 2021
Figure 57. Global Drugs for Non-Small Cell Lung Cancer Market Share Forecast by Application (2023-2028)
Figure 58. North America Drugs for Non-Small Cell Lung Cancer Sales Market Share by Type (2017-2028)
Figure 59. North America Drugs for Non-Small Cell Lung Cancer Sales Market Share by Application (2017-2028)
Figure 60. North America Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Country (2017-2028)
Figure 61. United States Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Canada Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Mexico Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Europe Drugs for Non-Small Cell Lung Cancer Sales Market Share by Type (2017-2028)
Figure 65. Europe Drugs for Non-Small Cell Lung Cancer Sales Market Share by Application (2017-2028)
Figure 66. Europe Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Country (2017-2028)
Figure 67. Germany Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. France Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. United Kingdom Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Russia Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Italy Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Sales Market Share by Type (2017-2028)
Figure 73. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Sales Market Share by Application (2017-2028)
Figure 74. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Region (2017-2028)
Figure 75. China Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Japan Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. South Korea Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. India Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Southeast Asia Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Australia Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. South America Drugs for Non-Small Cell Lung Cancer Sales Market Share by Type (2017-2028)
Figure 82. South America Drugs for Non-Small Cell Lung Cancer Sales Market Share by Application (2017-2028)
Figure 83. South America Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Country (2017-2028)
Figure 84. Brazil Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. Argentina Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 86. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales Market Share by Type (2017-2028)
Figure 87. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales Market Share by Application (2017-2028)
Figure 88. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Country (2017-2028)
Figure 89. Turkey Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 90. Saudi Arabia Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 91. UAE Drugs for Non-Small Cell Lung Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 92. Methodology
Figure 93. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
